# 2026-07369: FDA Fast-Tracks RSV Vaccine with Doomsday Priority Voucher

2026-07369, Notice of Approval of Product Under Priority Review Voucher; Material Threat Medical Countermeasure Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07369
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07369
- Title: Notice of Approval of Product Under Priority Review Voucher; Material Threat Medical Countermeasure Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20467
- Published: 2026-04-16
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Fast-Tracks RSV Vaccine with Doomsday Priority Voucher

## Summary

The FDA just gave a big thumbs-up to MRESVIA, a vaccine fighting Respiratory Syncytial Virus, using a special priority review voucher designed for urgent medical threats. This means faster approval for important health products that protect us from serious diseases. Companies and patients benefit from quicker access to life-saving vaccines without extra costs or delays.

## Abstract

The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat medical countermeasure (MCM) priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the issuance of material threat MCM priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that MRESVIA (Respiratory Syncytial Virus Vaccine), approved May 31, 2024, meets the redemption criteria.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-07369 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07369/notice-of-approval-of-product-under-priority-review-voucher-material-threat-medical-countermeasure)
- [2026-07369 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07369.pdf)

## Related
- [Previous: 2026-07368, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Re…](https://policyrisk.com/federal-register/2026-07368)
- [Next: 2026-07370, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Re…](https://policyrisk.com/federal-register/2026-07370)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07369 (as of 2026-06-08).